Greater blood pressure-lowering effect of the renin inhibitor EMD 58265 than an angiotensin-converting enzyme inhibitor in two-kidney one-clip Goldblatt rabbit

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 5-6, 2000, Pages 370-377

  Zimmerman, Ben G ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b 6 120 Jackson Hall ^*  (United States)

Author keywords

Angiotensin; Angiotensin converting enzyme inhibitor; Hypertension; Renin inhibitor; Renin angiotensin system

Indexed keywords

DITEKIREN; EMD 58265; ENALAPRILAT; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; RABBIT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; ENALAPRILAT; LIGATION; OLIGOPEPTIDES; RABBITS; RENAL CIRCULATION; RENIN;

EID: 0034022108     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03251.x     Document Type: Article

References (33)

1. 1. Haber E. Defining the physiologic and pathophysiologic roles of renin: The role of specific inhibitors. Am. J. Kidney Dis. 1985; 5: A14-22.
2. 2. Blaine EH, Schorn TW, Boger J. Statine-containing renin inhibitor: Dissociation of blood pressure lowering and renin inhibition in sodium-deficient dogs. Hypertension 1984; 6 (2PT2): I-111-18.
3. 3. Szelke M, Tree M, Leckie BJ et al. A transition-state analogue inhibitor of human renin (H.261): Test in vitro and a comparison with captopril in anaesthetized baboon. J. Hypertens. 1985; 3: 13-18.
4. 4. Zusman M, Burton J, Christensen D, Nussherger J, Dodds A, Haber E. Hemodynamic effects of a competitive renin inhibitor peptide in humans: Evidence for multiple mechanisms of action. Trans. Assoc. Am. Phys. 1983; 96: 365-74.
5. 5. Kleinen HD, Martin D, Chekal MA et al. Effects of the renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity. Hypertension 1988; 11: 613-19.
6. 6. Wood JM, Criscione L, de Gasparo M et al. CGP 38560: Orally active, low molecular-weight renin inhibitor with high potency and specificity. J. Cardiovasc. Pharmacol. 1989; 14: 221-6.
7. 7. Jeunemaitre X, Menard J, Nussberger J, Guyene TT, Brunner HR, Corvol P. Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38,56OA in hypertensive patients. Am. J. Hypertens. 1989; 2: 819-28.
8. 8. Pals DT, Ludens JH, DeGraaf GL. Systemic and renal hemodynamic effects of renin or angiotensin converting enzyme inhibition in nonhuman primates. J. Hypertens. 1989; 7 (Suppl. 2): S43-6.
9. 9. Patt WC, Hamilton HW, Ryan MJ et al. A novel active renin inhibitor containing 3-amino-4-thiazolyl-alanine at P2 with a long duration of action in a primate model of hypertension. Med. Chem. Res. 1992; 2: 10-15.
10. 10. Ryan MJ, Hicks GW, Batley BL et al. Effect of an orally active renin inhibitor CL-992 on blood pressure in normotensive and hypertensive monkeys. J. Pharmacol. Exp. Ther. 1994; 268: 372-9.
11. 11. Blaine EH, Nelson BJ, Seymour AA et al. Comparison of renin and converting enzyme inhibition in sodium-deficient dogs. Hypertension 1985; 7 (Suppl. I): 1-66-71.
12. 12. Hollenberg NK, Fisher NDL. Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hypertension 1995; 26: 602-9.
13. 13. Abdel-Ilah K, Amrani E, Menard J, Gonzales MF, Jean-Baptiste M. Effects of blocking the angiotensin II receptor, converting enzyme, and renin activity on the renal hemodynamics of normotensive guinea pigs. J. Curdiovasc. Pharmacol. 1993; 22: 231-9.
14. 14. Siragy HM, Howell NL, Peach MJ, Carey RM. Combined intrarenal blockade of the renin-angiotensin system in the conscious dog. Am. J. Phyziol. 1990; 258: F522-9.
15. 15. Verburg KM, Kadam JRC, Young AG, Rosenberg SH, Kleinert HD. Effect of intrarenal renin inhibition on renal hemodynamics and excretory function. Am. J. Physiol. 1990; 259: R7-14.
16. 16. Neisius D, Wood JM, Hofbauer KG. Renal vasodilatation after inhibition of renin or converting enzyme in marmoset. Am. J. Physiol. 1986; 251: H897-907.
17. 17. Birt PC, Zimmerman BG. Intrarenal arterial network renin content and inhibition by EMD 58265. Am. J. Hypertens. 1995; 8: 433-6.
18. 2 sites. J. Med. Chem. 1991; 34: 3267-80.
19. 19. Zimmerman BG, Finis CJ. Comparison of systemic and intrarenal converting enzyme inhibition by MK-422 on renal hemodynamics in conscious dogs. J. Cardiovasc. Pharmacol. 1985; 7: 715-22.
20. 20. McElroy ND, Zimmerman BG. Characterization of intrarenal arterial adrenergic receptors in renovascular hypertension. Hypertension 1989; 13: 851-8.
21. 21. Schaffer LW, Schorn TW, Winquist RJ et al. Acute hypotensive responses to peptide inhibitors of renin in conscious monkeys: An effect on blood pressure independent of plasma renin inhibition. J. Hypertens. 1990; 8: 251-9.
22. 22. Li T, Zimmerman BG. Relation between inhibition of renal angiotensin II production and local angiotensin generation. J. Hypertens. 1992; 10: 795-802.
23. 23. Zimmerman BG, Birt PC. Angiotensin II release from rabbit intrarenal arteries. Am. J. Hypertens. 1997; 10: 306-14.
24. 24. Hilgers KF, Kuczera M, Wilhelm MJ, Wiecek LA, Ritz E, Ganten D. Angiotensin formation in the isolated rat hindlimb. J. Hypertens. 1989; 7: 789-98.
25. 25. Zimmerman BG, Raich PC, Vavrek RJ, Stewart JM. Bradykinin contribution to renal blood flow effect of angiotensin converting enzyme inhibitor in the conscious sodium-restricted dog. Circ. Res. 1990; 66: 234-40.
26. 26. Pals DT, DeGraaf GL, Couch SJ, Brunden MN. Additive combination studies of captopril and ditekiren, a renin inhibitor, in nonhuman primates. Clin. Exp. Hypertens. 1991; A13: 425-36.
27. 27. Allan DR, Hui KY, Coletti C, Hollenberg NK. Renin vs angiotensin-converting enzyme inhibition in consequences for plasma and renal tissue angiotensin. J. Pharmacol. Exp. Ther. 1997; 283: 661-5.
28. 28. Zhang X, Dunham EW, Zimmerman BG. Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition. J. Hypertens. 1995; 13: 1413-19.
29. 1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats. Hypertension 1999; 33: 102-7.
30. 30. Allan DR, McKnight JA, Imre K, Coletti CM, Hollenberg NK. Converting enzyme inhibition and renal tissue angiotensin II in the rat. Hypertension 1994; 24: 516-22.
31. 31. Boucher R, Asselin J, Genest J. A new enzyme leading to direct formation of Ang II. Circ. Res. 1974; 34/35 (Suppl. I): 1-203-9.
32. 32. Karlsson C, Lindell F, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J. Clin. Endocrinol. Metab. 1998; 33: 3925-9.
33. 33. Li T, Zimmerman BG. β-Adrenergic-induced local angiotensin generation in the rabbit hind limb is dependent on the kidney. Hypertension 1991; 17: 1010-17.